You are here:

GlaxoSmithKline UK Ltd

Name SMC ID No Status Sub. Type
 
Abacavir 300mg tablets (Ziagen®) 174/05 Accepted Abbreviated Submission
Abacavir/lamivudine combination (Kivexa®) 175/05 Accepted Abbreviated Submission
albiglutide (Eperzan) 1024/15 Restricted Full submission
ambrisentan (Volibris) 511/08 Restricted Full submission
belimumab (Benlysta) 775/12 Not Recommended Full submission
belimumab (Benlysta) 775/12 Restricted Resubmission
dabrafenib (Tafinlar) 1023/15 Restricted Full submission
Dutasteride (Avodart®) 37/03 Accepted Full submission
dutasteride plus tamsulosin (Combodart) 628/10 Accepted Abbreviated Submission
eltrombopag (Revolade) 625/10 Restricted Full submission
eltrombopag (Revolade) 919/13 Accepted Full submission
fluticasone furoate (Avamys) 544/09 Accepted Full submission
fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) 1303/18 Restricted Abbreviated Submission
fluticasone furoate / vilanterol (Relvar Ellipta®) 966/14 Accepted Full submission
fluticasone furoate/vilanterol (Relvar Ellipta) 953/14 Restricted Full submission
Fluticasone, salmeterol (Seretide Accuhaler®) 82/03 Accepted Full submission
fondaparinux (Arixtra) 262/06 Not Recommended Non submission
fondaparinux (Arixtra) 420/07 Accepted Full submission
fondaparinux (Arixtra) 261/06 Not Recommended Non submission
fondaparinux sodium (Arixtra) 668/10 Not Recommended Non submission
fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra) 287/06 Not Recommended Full submission
fondiparinux sodium (Arixtra) 439/08 Accepted Full submission
fosamprenavir (Telzir) 431/07 Accepted Abbreviated Submission
fosamprenavir (Telzir) 431/07 Not Recommended Non submission
Fosamprenavir 700mg tablets and oral suspension 50mg/ml (Telzir®) 188/05 Accepted Full submission
lamivudine / zidovudine (Combivir) 569/09 Accepted Abbreviated Submission
lapatinib (Tyverb) 526/09 Not Recommended Full submission
lapatinib (Tyverb) 526/09 Not Recommended Resubmission
lapatinib (Tyverb) 768/12 Superseded Non submission
lapatinib (Tyverb) 925/13 Not Recommended Non submission
mepolizumab (Nucala) 1149/16 Restricted Full submission
nelarabine (Atriance) 454/08 Restricted Full submission
ofatumumab (Arzerra) 626/10 Not Recommended Full submission
pazopanib (Votrient) 676/11 Restricted Full submission
pazopanib (Votrient) 820/12 Not Recommended Full submission
retapamulin (Altargo) 472/08 Not Recommended Non submission
retigabine (Trobalt) 712/11 Restricted Full submission
ropinirole prolonged release (Requip XL) 491/08 Accepted Abbreviated Submission
ropinirole tablets (Adartrel) 165/05 Restricted Resubmission
Rosiglitazone (Avandia®) 91/04 Withdrawn Resubmission
Rosiglitazone (Avandia®) 91/04 Withdrawn Full submission
Rosiglitazone maleate (Avandia Triple Therapy®) 181/05 Withdrawn Abbreviated Submission
Rosiglitazone maleate/metformin hydrochloride (Avandamet®) 140/04 Withdrawn Abbreviated Submission
rosiglitazone/metformin 2mg/500mg, 2mg/1g, 4mg/1g (Avandamet) 281/06 Withdrawn Abbreviated Submission
rupatadine (Rupafin) 612/10 Withdrawn Non submission
salmeterol 25 mcg inhaler (Serevent Evohaler) 292/06 Accepted Abbreviated Submission
salmeterol fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler) 450/08 Not Recommended Full submission
salmeterol xinafoate fluticasone propionate combination inhaler (Seretide) 450/08 Not Recommended Resubmission
Seretide 50 Evohaler (Salmeterol xinafoate 25mcg/fluticasone propionate 50mcg) 108/04 Accepted Abbreviated Submission
Sumatriptan succinate (Imigran Radis®) 127/04 Accepted Abbreviated Submission
topotecan (Hycamtin) 421/07 Restricted Full submission
topotecan 1mg, 4mg powder for concentrate for solution for infusion hydrochloride (Hycamtin) 366/07 Superseded Full submission
topotecan hydrochloride (Hycamtin) 545/09 Superseded Full submission
umeclidinium (Incruse) 1004/14 Accepted Full submission
umeclidinium / vilanterol (Anoro) 978/14 Accepted Resubmission
umeclidinium/vilanterol (Anoro®) 978/14 Not Recommended Full submission
Vardenafil (Levitra®) 47/03 Accepted Full submission

Back